Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Simiao Sanjie granules
- Development stage
- Phase 1
- Lead developer
- Guang'anmen Hospital
- Administration
- Oral
01
Overview
Simiao Sanjie granules is a Traditional Chinese Medicine (TCM) herbal formulation developed by Guang'anmen Hospital of the China Academy of Chinese Medical Sciences. It is primarily indicated for the management of high-risk subsolid pulmonary nodules (SSNs), which are clinical precursors or early manifestations of lung adenocarcinoma. The formulation is designed based on TCM principles to "dissipate nodules" and "resolve phlegm," aiming to stabilize or reduce the size of pulmonary nodules and mitigate the risk of progression to lung cancer. It is currently undergoing clinical evaluation to determine its safety and efficacy in patients with persistent subsolid nodules.
- Other names
- 四妙散结颗粒Simiao Sanjie DecoctionSimiao Sanjie
Beyond the preview
Go deeper on Simiao Sanjie granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Simiao Sanjie granules.